Phathom Pharmaceuticals Inc. (PHAT)
PHAT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1783183/000119312526073379/0001193125-26-073379-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PHAT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001783183 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $175.1M |
| Net income | -$221.2M |
| Operating income | -$160.0M |
| Net margin | -126.3% |
| Operating margin | -91.4% |
| Revenue growth | +216.9% |
| Cash | $130.0M |
| Total assets | $259.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Including our existing cash and cash equivalents, we believe that we have sufficient working capital on hand to fund operations such that there is no substantial doubt as to our ability to continue as a going concern at the date the unaudited interim condensed financial statements were issued." | 10-Q 2026-10-29 |
| Cash and burn | $184.6M cash; operating cash flow -$5.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 81,291,520 (2026-10-27); 71,138,440 a year earlier; 57,252,519 three years earlier. | Cover page 2026-10-27 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-01-08 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Iselin, New Jersey, United States | PCAOB Form AP 2026-03-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $7K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $84.7M | -$13.9M | $1.8M | $184.6M | $165.5M | $274.9M | 10-Q 2026-10-29 |
| Q2 2026 2026-06-30 | $74.3M | -$17.6M | -$1.9M | $182.5M | $164.6M | $239.7M | 10-Q 2026-07-30 |
| Q1 2026 2026-03-31 | $58.3M | -$30.4M | -$15.6M | $180.9M | $163.7M | $204.9M | 10-Q 2026-04-30 |
| Q4 2025 2025-12-31 | $57.6M | -$21.1M | -$5.0M | $130.0M | $209.1M | $175.1M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $49.5M | -$30.0M | -$14.1M | $135.2M | $207.1M | $147.2M | 10-Q 2026-10-29 |
| Q2 2025 2025-06-30 | $39.5M | -$75.8M | -$62.7M | $149.6M | $205.1M | $114.0M | 10-Q 2026-07-30 |
| Q1 2025 2025-03-31 | $28.5M | -$94.3M | -$84.9M | $212.3M | $203.2M | $81.9M | 10-Q 2026-04-30 |
| Q4 2024 2024-12-31 | $29.7M | -$74.5M | -$63.5M | $297.3M | $201.4M | $55.3M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-01-08 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-10-29 |
| Latest current report | 8-K | 2026-10-29 |
| Latest proxy | DEFA14A | 2026-04-07 |
Source: SEC EDGAR submissions feed, 496 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +15.4% |
| 1 month | -13.4% |
| 3 months | -34.0% |
| Year to date | -63.5% |
| 1 year | -59.2% |
| From 52-week high | -66.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| STTK | Shattuck Labs Inc. | $4.66 | +0.21% | $474.6M |
| NGNE | Neurogene Inc. Common Stock | $23.30 | -2.63% | $482.3M |
| CAPR | Capricor Therapeutics Inc. | $8.30 | -12.91% | $482.6M |
| AQST | Aquestive Therapeutics Inc. | $3.76 | -3.84% | $472.6M |
| OCS | Oculis Holding AG | $7.63 | -0.13% | $469.9M |
| LYEL | Lyell Immunopharma Inc. | $14.65 | +2.45% | $469.0M |
| MNPR | Monopar Therapeutics Inc. | $71.97 | -0.04% | $487.7M |
| KMDA | Kamada Ltd. | $8.11 | +0.25% | $468.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier